Rhythm Pharmaceuticals Inc
RYTMHealthcare·Biotechnology·USA·Mid·NASD·Nov 13 • 7:00 AM ET
109.96+0.10 (0.09%)
2026-11-13 13:01 CET
Market cap
$7.62B
Revenue, TTM
280.75 USD m
Net income, TTM
-198.30 USD m
Free cash flow, TTM
-83.24 USD m
EPS diluted, TTM
-2.91
Price
RYTM against its 20, 50 and 200-day averagesPatternshover a marker to name it
10.0% under the 52-week high of 122.20 on 11 Dec 2025. 52-week low 74.50 on 30 Mar 2026. Last 15 sessions, 41.2% high to low
Volume 0.01× normal · the line is the 50-bar volume average
Setup. RS line 55
CANSLIM 4 of 6 — fails: EPS Growth This Year: High (>25%); Performance: Year +50%
VCP 3 of 6 — fails: 50-Day Simple Moving Average: SMA50 above SMA200; Average True Range: Under 2; RSI (14): Not Overbought (<60)
Minervini 2 of 4 — fails: 50-Day Simple Moving Average: SMA50 above SMA200; Performance: Year +50%
Zanger 3 of 5 — fails: Performance: Week +10%; Relative Volume: Over 1.5
Leaders 4 of 5 — fails: Performance: Year +50%
Breakout 2 of 4 — fails: 52-Week High/Low: New High; Relative Volume: Over 2
Growth 2 of 4 — fails: EPS Growth This Year: High (>25%); Return on Equity: Over +15%
Quality 1 of 5 — fails: Return on Equity: Over +15%; Net Profit Margin: High (>20%); Debt/Equity: Low (<0.1) — not on the tape: P/E: Under 25
Value 0 of 4 — fails: P/B: Under 2; Return on Equity: Over +15%; Debt/Equity: Low (<0.1) — not on the tape: P/E: Under 15
Income 0 of 4 — fails: Dividend Growth: Growing 2+ Years — not on the tape: Dividend Yield: Over 2%; Payout Ratio: Low (<20%); P/E: Under 25
Small Cap 3 of 4 — fails: Performance: Year +50%
Accumulation 3 of 4 — fails: Institutional Transactions: Over +10%
Relative Strength 2 of 3 — fails: Performance: Year +100%
Profile
RYTM52-week range, 74% of the way up
74.50122.20
Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with rare diseases. The firm offers IMCIVREE (setmelanotide), a precision medicine designed to treat hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. It is also involved in the clinical development program for setmelanotide in other rare MC4R pathway diseases, as well as a preclinical suite of investigational candidates for the treatment of congenital hyperinsulinism. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.
| Index | RUT |
|---|---|
| Employees | 414 |
| IPO | Oct 05, 2017 |
| Beta | 2.13 |
| ATR, 14d | 4.88 |
| Rel volume | 0.01 |
| Short float | 17.53% |
| Insider own | 3.96% |
| Inst own | 109.90% |
Snapshot
6 groupsValuation
| Index | RUT |
|---|---|
| Market Cap | $7.62B |
| Enterprise Value | 7.52B |
| Income | -198.30M |
| Sales | 280.75M |
| Book / share | 1.27 |
| Cash / share | 4.63 |
| Dividend Est. | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Dividend Gr. 3/5Y | - - |
| Payout | - |
| Employees | 414 |
| IPO | Oct 05, 2017 |
Ratios
| Price / earnings | - |
|---|---|
| Forward price / earnings | - |
| Price / earnings / growth | - |
| Price / sales | 27.15 |
| Price / book | 86.65 |
| Price / cash | 23.75 |
| Price / free cash flow | - |
| Value / cash profit | - |
| Value / sales | 26.79 |
| Quick Ratio | 2.57 |
| Current Ratio | 2.78 |
| Debt / equity | 0.53 |
| Long-term debt / equity | 0.45 |
| Options and short | Yes / Yes |
Earnings
| Earnings / share | -2.91 |
|---|---|
| Earnings next year | -1.03 |
| Earnings next quarter | -2.59 |
| Earnings this year | -54.37% |
| Earnings next year | 78.47% |
| Earnings growth, 5 years | - |
| Past earnings growth | 3.66% -0.46% |
| Past sales growth | 100.23% - |
| Earnings vs last year | 6.14% |
| Sales vs last year | 61.04% |
| Earnings vs last quarter | 25.12% |
| Sales vs last quarter | 79.59% |
| Earnings | Nov 03 BMO |
| Surprise | 14.05% 7.67% |
Ownership
| Insiders own | 3.96% |
|---|---|
| Insider trades | -9.85% |
| Institutions own | 109.90% |
| Institution trades | 3.34% |
| Return on assets | -40.80% |
| Return on equity | -110.64% |
| Return on capital | -66.32% |
| Gross Margin | 88.17% |
| Operating margin | -66.70% |
| Profit Margin | -70.63% |
| 20-day average | 11.40% |
| 50-day average | 13.62% |
| 200-day average | 13.11% |
Technical
| Shares out | 69.31M |
|---|---|
| Shares floating | 66.59M |
| Short / float | 17.53% |
| Short ratio | 11.78 |
| Short interest | 11.68M |
| 52-week high | 122.20 -10.0% |
| 52-week low | 74.50 +47.6% |
| Volatility | 4.12% 5.17% |
| Average range | 4.88 |
| Strength index | 62.17 |
| Market sensitivity | 2.13 |
| Relative volume | 0.01 |
| Avg Volume | 991.49K |
| Volume | 557 |
Performance
| Perf Week | -2.07% |
|---|---|
| Perf Month | 25.00% |
| Perf Quarter | -4.75% |
| Perf Half Y | 21.48% |
| Perf YTD | 2.73% |
| Perf Year | 14.67% |
| Perf 3Y | 283.94% |
| Perf 5Y | 734.93% |
| Perf 10Y | - |
| Recommendation | 1.20 |
| Target Price | 140.12 |
| Prev Close | 109.86 |
| Price | 109.96 |
| Change % | 0.09% |
Analyst ratings
latest 10 of 20| Date | Action | Analyst | Rating change | Target | Implied |
|---|---|---|---|---|---|
| Oct 16, 2026 | Initiated | William Blair | Outperform | ||
| Sep 17, 2026 | Initiated | Wolfe Research | Outperform | ||
| Sep 14, 2026 | Resumed | Leerink Partners | Outperform | $133 | +21.0% |
| Aug 28, 2026 | Initiated | Deutsche Bank | Hold | $120 | +9.1% |
| Jul 27, 2026 | Initiated | JP Morgan | Overweight | $145 | +31.9% |
| Feb 19, 2026 | Initiated | RBC Capital Mkts | Outperform | $478 | +334.7% |
| Nov 25, 2025 | Initiated | Citigroup | Buy | $136 | +23.7% |
| Nov 05, 2025 | Downgrade | Oppenheimer | Outperform → Perform | ||
| Jul 10, 2025 | Initiated | Goldman | Buy | $97 | -11.8% |
| Jul 07, 2025 | Initiated | Leerink Partners | Outperform | $88 | -20.0% |
Peers
Mkt cap| Ticker | Company | Mkt cap |
|---|---|---|
| ACAD | Acadia Pharmaceuticals Inc | 3.14B |
| AARD | Aardvark Therapeutics Inc | 33.26M |
| VKTX | Viking Therapeutics Inc | 3.54B |
| ASND | Ascendis Pharma A/S | 17.73B |
| GPCR | Structure Therapeutics Inc ADR | 1.42B |
| BMRN | Biomarin Pharmaceutical Inc | 10.95B |
| HRMY | Harmony Biosciences Holdings Inc | 1.98B |
| NBIX | Neurocrine Biosciences Inc | 17.31B |
| LLY | Lilly(Eli) & Co | 1345.17B |
| NVO | Novo Nordisk ADR | 135.84B |
Insider trading
latest 14 of 45| Insider | Relationship | Date | Transaction | Cost | Shares | Value | Total held | Form |
|---|---|---|---|---|---|---|---|---|
| Meeker David P | President and CEO | Sep 14 '26 | Option Exercise | 6.05 | 50,000 | 302,500 | 289,258 | Sep 14 07:37 PM |
| Meeker David P | President and CEO | Sep 14 '26 | Sale | 102.67 | 50,000 | 5,133,442 | 239,258 | Sep 14 07:37 PM |
| David Meeker | Director | Sep 14 '26 | Proposed Sale | 104.71 | 50,000 | 5,235,500 | Sep 14 04:49 PM | |
| Smith Hunter C | Chief Financial Officer | Aug 31 '26 | Option Exercise | 25.79 | 57,187 | 1,474,853 | 176,798 | Sep 01 04:22 PM |
| Smith Hunter C | Chief Financial Officer | Aug 31 '26 | Sale | 105.46 | 62,774 | 6,619,913 | 114,024 | Sep 01 04:22 PM |
| HUNTER SMITH | Officer | Aug 31 '26 | Proposed Sale | 107.17 | 62,774 | 6,727,490 | Aug 31 04:32 PM | |
| Shulman Joseph | Chief Technical Officer | Aug 13 '26 | Option Exercise | 6.80 | 2,024 | 13,763 | 20,994 | Aug 17 06:00 PM |
| Shulman Joseph | Chief Technical Officer | Aug 13 '26 | Sale | 119.75 | 5,079 | 608,210 | 15,915 | Aug 17 06:00 PM |
| Garfield Alastair | Chief Scientific Officer | Aug 13 '26 | Sale | 117.57 | 7,763 | 912,703 | 2,295 | Aug 17 05:57 PM |
| Lee Jennifer Kayden | EVP, Head of North America | Aug 13 '26 | Option Exercise | 17.62 | 56,601 | 997,037 | 75,834 | Aug 14 07:04 PM |
| Lee Jennifer Kayden | EVP, Head of North America | Aug 13 '26 | Sale | 117.38 | 75,834 | 8,901,531 | 0 | Aug 14 07:04 PM |
| Mazabraud Yann | EVP, Head of International | Aug 12 '26 | Option Exercise | 6.80 | 46,625 | 317,050 | 112,655 | Aug 14 07:01 PM |
| Mazabraud Yann | EVP, Head of International | Aug 12 '26 | Sale | 116.15 | 57,000 | 6,620,575 | 55,655 | Aug 14 07:01 PM |
| ALASTAIR GARFIELD | Officer | Aug 13 '26 | Proposed Sale | 117.60 | 7,763 | 912,929 | Aug 13 04:51 PM |
Held by
AUM| Ticker | Company | AUM |
|---|---|---|
| VTI | Vanguard Morningstar Total Stock Market ETF | AUM: 696.31B |
| IWM | iShares Russell 2000 Index Fund | AUM: 77.86B |
| VB | Vanguard Morningstar Small-Cap ETF | AUM: 80.23B |
| XBI | State Street SPDR S&P Biotech ETF | AUM: 10.59B |
| VBK | Vanguard Morningstar Small-Cap Growth ETF | AUM: 22.68B |
| VXF | Vanguard Extended Market Index ETF | AUM: 30.79B |
| IWO | iShares Russell 2000 Growth ETF | AUM: 14.25B |
| IBB | iShares Biotechnology ETF | AUM: 11.39B |
| SCHA | Schwab U.S. Small-Cap ETF | AUM: 22.44B |
| VTWO | Vanguard Russell 2000 Index ETF | AUM: 16.90B |
News
latest 14 of 200- AstraZeneca's Reported $10 Billion Rhythm Bid Raises the Stakes for Palatin's Obesity Pipeline (NASDAQ: PTN) (FinanceWire)
- Palatin's Peptide Is Advancing Toward the Clinic as Big Pharma Pays Billions for Early Peptides (NASDAQ: PTN) (FinanceWire)
- RYTM Stock Clocks Best Day In Nearly 16 Months On AstraZeneca $10B Bid Report (Stocktwits) +28.04% -5.11%
- Rhythm Pharmaceuticals stock surges 28% on AstraZeneca bid report (Investing.com)
- AstraZeneca Made $10 Billion Offer for Rhythm Pharmaceuticals (The Wall Street Journal)
- Rhythm Pharmaceuticals Announces NICE Guidance for IMCIVREE (Setmelanotide) Updated to Include Adults Living with Bardet-Biedl Syndrome (GlobeNewswire)
- Rhythm Pharmaceuticals Beats As Hypothalamic Obesity Launch Accelerates, But New Debt And LG Chem Payments Recast The Story (Earnings Whispers) -7.49%
- Rhythm Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update (GlobeNewswire)
- Rhythm Pharmaceuticals and LG Chem Enter into Amendment to Bivamelagon Exclusive License Agreement (GlobeNewswire)
- Rhythm's Incivri Launch Faces Its First Real Test As Street Bets On 18% Sequential Jump (Earnings Whispers)
- Big Pharma's Obesity Shopping Spree Is Moving Beyond GLP-1s. Palatin May Fit the Pattern (NASDAQ: PTN) (FinanceWire)
- Rhythm Pharmaceuticals to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026 (GlobeNewswire)
- Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE (setmelanotide) in Japan for Patients with Acquired Hypothalamic Obesity (GlobeNewswire)
- Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE (setmelanotide) for Weight Management in Adult and Pediatric Patients 4 years of Age and Older with Acquired Hypothalamic Obesity (GlobeNewswire)
Quarterly earnings
2026Q3 EPS -0.610 beat -0.710, from -0.820 a year earlier. Sales 92.13 beat 85.56, from 51.30 a year earlier
The outline behind the bar is the estimate. The filled bar is the print. Green beat it, red missed it.
| Period | Reported | EPS adjusted | EPS est | EPS reported | Sales act, USD m | Sales est, USD m | Surprise | Year-ago quarter | Analysts | Next session |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026Q3ended 2026-09-30 | 2026-11-03 08:30 | -0.610 | -0.710 | -0.610 | 92.13 | 85.56 | EPS -14.0% · sales +7.7% | vs 2025Q3, year-ago quarter · EPS -25.6% · sales +79.6% | 18 | Open -9.21% vs SPY +0.08%. Close -7.49% vs SPY +0.30% |
| 2026Q2ended 2026-06-30 | 2026-08-04 08:30 | -0.730 | -0.807 | -0.734 | 71.26 | 67.66 | EPS -9.6% · sales +5.3% | vs 2025Q2, year-ago quarter · EPS -2.7% · sales +46.9% | 16 EPS · 15 sales | Open -2.04% vs SPY +0.39%. Close +2.92% vs SPY +1.80% |
| 2026Q1ended 2026-03-31 | 2026-05-05 08:30 | -0.830 | -0.822 | -0.835 | 60.11 | 55.78 | EPS +1.0% · sales +7.8% | vs 2025Q1, year-ago quarter · EPS +2.5% · sales +83.8% | 15 EPS · 14 sales | Open +9.72% vs SPY +0.52%. Close +7.86% vs SPY +0.80% |
| 2025Q4ended 2025-12-31 | 2026-02-26 08:30 | -0.730 | -0.805 | -0.730 | 57.25 | 56.21 | EPS -9.3% · sales +1.9% | vs 2024Q4, year-ago quarter · EPS +1.4% · sales +36.9% | 15 | Open +4.14% vs SPY +0.02%. Close -1.09% vs SPY -0.56% |
| 2025Q3ended 2025-09-30 | 2025-11-04 08:30 | -0.820 | -0.708 | -0.819 | 51.30 | 50.71 | EPS +15.8% · sales +1.2% | vs 2024Q3, year-ago quarter · EPS +12.3% · sales +54.3% | 14 EPS · 13 sales | Open -9.92% vs SPY -1.06%. Close -7.69% vs SPY -1.19% |
| 2025Q2ended 2025-06-30 | 2025-08-05 08:30 | -0.750 | -0.670 | -0.753 | 48.50 | 43.64 | EPS +11.9% · sales +11.1% | vs 2024Q2, year-ago quarter · EPS +36.4% · sales +66.8% | 14 EPS · 13 sales | Open -3.38% vs SPY +0.10%. Close -1.85% vs SPY -0.51% |
| 2025Q1ended 2025-03-31 | 2025-05-07 08:30 | -0.810 | -0.694 | -0.806 | 32.70 | 40.16 | EPS +16.7% · sales -18.6% | vs 2024Q1, year-ago quarter · EPS -65.5% · sales +25.9% | 12 EPS · 11 sales | Open -2.62% vs SPY +0.24%. Close +3.06% vs SPY +0.42% |
| 2024Q4ended 2024-12-31 | 2025-02-26 08:30 | -0.720 | -0.694 | -0.725 | 41.83 | 38.48 | EPS +3.8% · sales +8.7% | vs 2023Q4, year-ago quarter · EPS +2.9% · sales +72.6% | 11 EPS · 10 sales | Open +1.39% vs SPY +0.28%. Close +4.49% vs SPY +0.05% |
| 2024Q3ended 2024-09-30 | 2024-11-05 16:30 | -0.730 | -0.805 | -0.735 | 33.25 | 32.52 | EPS -9.3% · sales +2.2% | vs 2023Q3, year-ago quarter · EPS -3.9% · sales +47.8% | 11 EPS · 10 sales | Open +6.67% vs SPY +2.17%. Close +11.38% vs SPY +2.49% |
| 2024Q2ended 2024-06-30 | 2024-08-06 08:30 | -0.550 | -0.709 | -0.550 | 29.08 | 28.79 | EPS -22.4% · sales +1.0% | vs 2023Q2, year-ago quarter · EPS -32.9% · sales +51.3% | 9 EPS · 8 sales | Open +4.25% vs SPY +0.36%. Close +0.02% vs SPY +0.92% |
| 2024Q1ended 2024-03-31 | 2024-05-07 08:30 | -2.350 | -2.356 | -2.351 | 25.97 | 26.90 | EPS -0.3% · sales -3.5% | vs 2023Q1, year-ago quarter · EPS +155.4% · sales +126.4% | 8 | Open -6.88% vs SPY +0.19%. Close -10.32% vs SPY +0.11% |
| 2023Q4ended 2023-12-31 | 2024-02-22 08:30 | -0.700 | -0.706 | -0.703 | 24.23 | 25.38 | EPS -0.8% · sales -4.5% | vs 2022Q4, year-ago quarter · EPS -6.7% · sales +175.7% | 9 EPS · 8 sales | Open +0.39% vs SPY +1.37%. Close -9.73% vs SPY +2.07% |
| 2023Q3ended 2023-09-30 | 2023-11-07 08:30 | -0.760 | -0.740 | -0.763 | 22.50 | 22.18 | EPS +2.7% · sales +1.5% | vs 2022Q3, year-ago quarter · EPS -3.8% · sales +425.3% | 9 EPS · 8 sales | - |
| 2023Q2ended 2023-06-30 | 2023-08-01 08:30 | -0.820 | -0.798 | -0.821 | 19.22 | 15.03 | EPS +2.8% · sales +27.9% | vs 2022Q2, year-ago quarter · EPS -7.9% · sales +112.0% | 9 EPS · 8 sales | - |
| 2023Q1ended 2023-03-31 | 2023-05-02 08:30 | -0.920 | -0.718 | -0.920 | 11.47 | 12.12 | EPS +28.2% · sales -5.4% | vs 2022Q1, year-ago quarter · EPS -12.4% · sales +665.6% | 8 | - |
| 2022Q4ended 2022-12-31 | 2023-03-01 08:30 | -0.750 | -0.809 | -0.755 | 8.79 | 7.22 | EPS -7.3% · sales +21.8% | vs 2021Q4, year-ago quarter · EPS -11.8% · sales +383.8% | 9 EPS · 8 sales | - |
Annual earnings
2025FY EPS -3.110 beat -3.174, from -4.340 a year earlier. Sales 194.77 beat 188.99, from 130.13 a year earlier
Reported years only. The outline behind the bar is the estimate. A later year with no print stays in the table.
earnings feed, not the snapshot. Not the statement ratio.
| Period | EPS adjusted | EPS est | EPS reported | Sales act, USD m | Sales est, USD m | P/E, earnings feed |
|---|---|---|---|---|---|---|
| 2030FYestimate | - | 10.001 | - | - | 1,763 | 11.00 |
| 2029FYestimate | - | 5.584 | - | - | 1,264 | 19.69 |
| 2028FYestimate | - | 1.669 | - | - | 870.5 | 65.90 |
| 2027FYestimate | - | -1.033 | - | - | 572.69 | - |
| 2026FYestimate | - | -4.801 | - | - | 332.01 | - |
| 2025FY | -3.110 | -3.174 | -3.110 | 194.77 | 188.99 | - |
| 2024FY | -4.340 | -4.322 | -4.338 | 130.13 | 126.95 | - |
| 2023FY | -3.200 | -3.201 | -3.202 | 77.43 | 78.80 | - |
| 2022FY | -3.470 | -3.533 | -3.475 | 23.64 | 21.41 | - |
| 2021FY | -1.400 | -1.447 | -1.404 | 3.15 | 3.03 | - |
| 2020FY | -3.040 | -3.018 | -3.037 | 0.00 | 0.05 | - |
| 2019FY | -3.860 | -3.900 | -3.864 | 0.00 | 0.00 | - |
| 2018FY | -2.390 | -2.208 | -2.389 | 0.00 | 0.00 | - |
| 2017FY | -2.830 | -1.937 | -2.830 | - | 0.00 | - |
Quarterly results
2026Q3 revenue 92.13, from 51.30 a year earlier. Operating margin -42.6%, from -102.63% a year earlier
From the quarterly statement. Not an estimate.
Estimate revisions
Latest snapshot of each period and type. 2026FY E -4.80 per share.
| Period | Type | Scale | Date | Mean | vs prior date |
|---|---|---|---|---|---|
| 2026FY | E | per share | 2026-11-05 | -4.80 | +5.6% |
| 2026Q4 | E | per share | 2026-11-05 | -2.59 | +10.8% |
| 2026FY | R | per share | 2026-11-05 | -5.39 | +13.8% |
| 2026Q4 | R | per share | 2026-11-05 | -3.22 | +25.2% |
| 2026FY | S | - | 2026-11-05 | 332.01 | +0.1% |
| 2026Q4 | S | - | 2026-11-05 | 109.65 | +0.1% |
| 2026Q3 | E | per share | 2026-10-28 | -0.71 | -0.1% |
| 2026Q3 | S | per share | 2026-10-28 | 85.57 | +0.1% |
| 2026Q3 | R | per share | 2026-10-27 | -0.69 | 0.0% |
| 2026Q2 | E | per share | 2026-07-24 | -0.81 | -0.6% |
| 2026Q2 | R | per share | 2026-07-24 | -0.83 | -2.0% |
| 2026Q2 | S | per share | 2026-07-24 | 67.66 | +0.5% |
| 2026Q1 | E | per share | 2026-04-15 | -0.83 | -0.2% |
| 2026Q1 | R | per share | 2026-04-15 | -0.84 | -0.7% |
| 2026Q1 | S | per share | 2026-04-15 | 55.78 | +0.3% |
| 2025FY | E | per share | 2026-02-19 | -3.17 | +0.0% |
| 2025Q4 | E | per share | 2026-02-19 | -0.80 | +0.0% |
| 2025FY | S | - | 2026-02-19 | 188.99 | +0.0% |
| 2025Q4 | S | per share | 2026-02-17 | 56.21 | +0.1% |
| 2025FY | R | per share | 2026-01-30 | -3.10 | +2.6% |
| 2025Q4 | R | per share | 2026-01-18 | -0.74 | 0.0% |
| 2025Q3 | E | per share | 2025-11-02 | -0.71 | 0.0% |
| 2025Q3 | R | per share | 2025-10-22 | -0.66 | +0.4% |
| 2025Q3 | S | per share | 2025-10-22 | 50.71 | -0.4% |
| 2025Q2 | E | per share | 2025-07-25 | -0.67 | +0.1% |
| 2025Q2 | R | per share | 2025-07-21 | -0.66 | 0.0% |
| 2025Q2 | S | per share | 2025-07-21 | 43.64 | 0.0% |
| 2025Q1 | E | per share | 2025-04-11 | -0.69 | +0.2% |
| 2025Q1 | S | per share | 2025-04-11 | 40.16 | -0.4% |
| 2025Q1 | R | per share | 2025-04-08 | -0.73 | +1.4% |
| 2024FY | E | per share | 2025-02-26 | -4.28 | -0.9% |
| 2024Q4 | E | per share | 2025-02-26 | -0.65 | -6.0% |
| 2024Q4 | S | per share | 2025-02-26 | 39.07 | +1.5% |
| 2024FY | S | - | 2025-02-26 | 127.51 | +0.4% |
| 2024FY | R | per share | 2025-02-04 | -4.24 | +0.4% |
| 2024Q4 | R | per share | 2025-01-20 | -0.63 | 0.0% |
| 2024Q3 | S | per share | 2024-11-01 | 32.52 | +0.3% |
| 2024Q3 | R | per share | 2024-10-29 | -0.76 | +3.0% |
| 2024Q3 | E | per share | 2024-10-23 | -0.80 | 0.0% |
| 2024Q2 | S | per share | 2024-07-23 | 28.79 | 0.0% |
| 2024Q2 | E | per share | 2024-07-21 | -0.71 | 0.0% |
| 2024Q2 | R | per share | 2024-07-21 | -0.74 | 0.0% |
| 2024Q1 | S | per share | 2024-04-17 | 26.90 | -0.5% |
| 2024Q1 | E | per share | 2024-04-11 | -2.36 | +0.1% |
| 2024Q1 | R | per share | 2024-04-11 | -2.36 | +0.3% |
| 2023FY | E | per share | 2024-02-08 | -3.20 | +0.1% |
| 2023FY | R | per share | 2024-02-08 | -3.20 | +0.2% |
| 2023FY | S | per share | 2024-02-08 | 78.80 | -0.3% |
Estimate history
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | MRQ |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS per share | -2.83 | -2.389 | -3.864 | -3.037 | -1.404 | -3.475 | -3.202 | -4.338 | -3.107 | -2.9127 | - |
| Sales USD millions | 0 | 0 | 0 | 0 | 3 | 24 | 77 | 130 | 190 | 281 | - |
| Shares million shares | 27 | 34 | 44 | 44 | 50 | 57 | 59 | 62 | 67 | - | 69 |
| Metric | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|---|
| EPS per share | -0.735 | -0.725 | -0.806 | -0.753 | -0.819 | -0.73 | -0.835 | -0.734 | -0.613 |
| Sales USD millions | 33 | 42 | 33 | 49 | 51 | 57 | 60 | 71 | 92 |
| Shares million shares | 61 | 62 | 63 | 64 | 67 | 67 | 68 | 69 | 69 |
Income statement, annual
| Metric | TTM | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 | 2018FY12/31/2018 |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 280.75 | 189.76+45.8% | 130.13+68.1% | 77.43+227.5% | 23.64+650.5% | 3.15 | 0.00 | 0.00 | 0.00 |
| Cost of Goods Sold Incl. D&A | 33.21 | 19.93+41.5% | 14.08+37.9% | 10.21+237.0% | 3.03+113.4% | 1.42+105.8% | 0.69-16.9% | 0.83+88.6% | 0.44 |
| Gross Profit | 247.54 | 169.83+46.3% | 116.05+72.6% | 67.22+226.2% | 20.61+1084.5% | 1.74 | -0.69 | -0.83 | -0.44 |
| Selling, General and Administrative Excl. Other | 434.79 | 361.84-5.2% | 381.55+51.7% | 251.58+25.9% | 199.77+16.3% | 171.80+26.4% | 135.88-6.4% | 145.17+86.2% | 77.97 |
| Research and Development | 179.51 | 166.90-29.7% | 237.25+77.0% | 134.05+24.4% | 107.73+4.3% | 103.31+15.1% | 89.76-18.0% | 109.45+117.4% | 50.34 |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -187.25 | -192.02 | -265.50 | -184.36 | -179.16 | -170.06 | -136.57 | -146.00 | -78.42 |
| Interest Expense | 18.23 | 20.58-0.1% | 20.60+48.3% | 13.89+167.1% | 5.20 | 0.00 | 0.00 | 0.00 | 0.00 |
| Unusual Expense | 0.85 | 0.91 | -7.48 | -0.19 | -0.25 | 0.00 | 0.00 | - | 0.00 |
| Net Income Before Taxes | -192.24 | -196.04 | -260.26 | -184.11 | -181.12 | -69.61 | -134.00 | -140.73 | -74.06 |
| Income Taxes | 1.57 | 0.50+42.9% | 0.35-37.5% | 0.56 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Consolidated Net Income | -193.81 | -196.54 | -260.60 | -184.68 | -181.12 | -69.61 | -134.00 | -140.73 | -74.06 |
| Net Income From Continuing Operations | -193.81 | -196.54 | -260.60 | -184.68 | -181.12 | -69.61 | -134.00 | -140.73 | -74.06 |
| Net Income | -198.30 | -201.92 | -264.57 | -184.68 | -181.12 | -69.61 | -134.00 | -140.73 | -74.06 |
| EPS (Recurring) per share | -2.86 | -3.10 | -4.42 | -3.20 | -3.48 | -1.40 | -3.04 | -3.86 | -2.39 |
| EPS (Basic, Before Extraordinaries) per share | -2.91 | -3.11 | -4.34 | -3.20 | -3.48 | -1.40 | -3.04 | -3.86 | -2.39 |
| EPS (Diluted) per share | -2.91 | -3.11 | -4.34 | -3.20 | -3.48 | -1.40 | -3.04 | -3.86 | -2.39 |
| EBITDA | -186.22 | -190.68 | -263.94 | -182.60 | -177.75 | -168.90 | -135.88 | -145.17 | -77.97 |
| Non-Operating Income (Expense) | 14.09 | 17.47-4.9% | 18.37+31.7% | 13.95+366.6% | 2.99-97.0% | 100.45+3793.4% | 2.58-51.0% | 5.27+21.1% | 4.35 |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 73.82 | 52.79+68.4% | 31.35+21.9% | 25.72+29.7% | 19.83-4.7% | 20.80+19.2% | 17.45+46.9% | 11.88+90.4% | 6.24 |
| Price To Sales Ratio ratio | 23.42 | 36.66 | 26.24 | 34.24 | 64.21 | 156.95 | - | - | - |
| Gross Margin % | 88.17 | 89.50 | 89.18 | 86.82 | 87.19 | 55.14 | - | - | - |
| Operating Margin % | -66.70 | -101.19 | -204.04 | -238.10 | -757.92 | -5,391.85 | - | - | - |
| Net Margin % | -70.63 | -106.41 | -203.32 | -238.52 | -766.22 | -2,207.10 | - | - | - |
| Shares Outstanding million shares | 69.31 | 67.21+7.7% | 62.39+5.0% | 59.43+5.0% | 56.61+12.6% | 50.28+13.7% | 44.24+0.5% | 44.00+27.9% | 34.41 |
| Market Capitalization | 7,616.69 | 7,616.69+121.4% | 3,440.37+26.6% | 2,716.67+65.6% | 1,640.86+227.1% | 501.68-61.8% | 1,314.21+65.8% | 792.46-14.3% | 924.97 |
Income statement, quarterly
| Metric | 2026Q39/30/2026 | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 92.13+79.6% | 71.25+46.9% | 60.11+83.8% | 57.25+36.9% | 51.30+54.3% | 48.50+66.8% | 32.70+25.9% | 41.83+72.6% |
| Cost of Goods Sold Incl. D&A | 12.21+118.0% | 8.98+57.0% | 7.21+88.7% | 4.80+21.2% | 5.60+40.0% | 5.72+83.3% | 3.82+27.3% | 3.96+15.1% |
| Gross Profit | 79.91+74.9% | 62.27+45.6% | 52.90+83.1% | 52.45+38.5% | 45.70+56.2% | 42.78+64.9% | 28.89+25.8% | 37.87+82.1% |
| Selling, General and Administrative Excl. Other | 119.18+21.2% | 110.83+25.8% | 105.26+38.7% | 99.51+25.8% | 98.35+34.5% | 88.08+32.6% | 75.89-53.4% | 79.13+27.5% |
| Research and Development | 52.43+14.2% | 43.38+3.0% | 41.67+13.2% | 42.03+2.5% | 45.92+21.6% | 42.13+40.3% | 36.80-71.4% | 41.00+38.1% |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -39.27 | -48.55 | -52.36 | -47.06 | -52.65 | -45.30 | -47.00 | -41.26 |
| Interest Expense | 4.50-5.1% | 4.54-22.0% | 4.58-15.3% | 4.62-15.2% | 4.74-9.5% | 5.82+26.5% | 5.41+13.9% | 5.45+35.6% |
| Unusual Expense | 0.16-55.6% | 0.23-32.4% | 0.33+312.5% | 0.13+8.3% | 0.36-29.4% | 0.34 | 0.08 | 0.12 |
| Net Income Before Taxes | -40.76 | -48.85 | -55.09 | -47.54 | -52.79 | -46.30 | -49.42 | -43.38 |
| Income Taxes | 0.61+454.5% | 0.44+29.4% | 0.55+587.5% | -0.03 | 0.11 | 0.34-29.2% | 0.08-73.3% | -0.09-145.0% |
| Consolidated Net Income | -41.37 | -49.30 | -55.64 | -47.51 | -52.90 | -46.63 | -49.50 | -43.29 |
| Net Income From Continuing Operations | -41.37 | -49.30 | -55.64 | -47.51 | -52.90 | -46.63 | -49.50 | -43.29 |
| Net Income | -42.35 | -50.36 | -56.74 | -48.84 | -54.28 | -47.98 | -50.82 | -44.63 |
| EPS (Recurring) per share | -0.61 | -0.73 | -0.83 | -0.73 | -0.82 | -0.75 | -0.81 | -0.72 |
| EPS (Basic, Before Extraordinaries) per share | -0.61 | -0.73 | -0.83 | -0.73 | -0.82 | -0.75 | -0.81 | -0.72 |
| EPS (Diluted) per share | -0.61 | -0.73 | -0.83 | -0.73 | -0.82 | -0.75 | -0.81 | -0.72 |
| EBITDA | -39.02 | -48.30 | -52.11 | -46.79 | -52.35 | -44.92 | -46.62 | -40.87 |
| Non-Operating Income (Expense) | 3.17-36.1% | 4.47-13.4% | 2.18-29.2% | 4.27+24.1% | 4.96-12.2% | 5.16-9.2% | 3.080.0% | 3.44-9.9% |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 19.77+33.0% | 20.58+64.0% | 18.25+79.6% | 15.22+82.5% | 14.86+71.0% | 12.55+53.4% | 10.16+65.5% | 8.34+21.8% |
| Price To Sales Ratio ratio | 23.42 | 31.74 | 27.22 | 37.72 | 38.38 | 25.75 | 24.41 | 26.50 |
| Gross Margin % | 86.74 | 87.39 | 88.01 | 91.61 | 89.08 | 88.20 | 88.33 | 90.54 |
| Operating Margin % | -42.63 | -68.14 | -87.11 | -82.20 | -102.64 | -93.39 | -143.73 | -98.63 |
| Net Margin % | -45.97 | -70.68 | -94.40 | -85.30 | -105.81 | -98.93 | -155.39 | -106.70 |
| Shares Outstanding million shares | 69.31+3.9% | 68.82+7.7% | 68.45+7.8% | 67.21+7.7% | 66.68+8.5% | 63.91+4.6% | 63.49+4.2% | 62.39+5.0% |
| Market Capitalization | 7,616.69+13.6% | 7,615.95+89.4% | 5,938.75+77.3% | 7,143.43+107.6% | 6,707.77+109.4% | 4,020.24+60.6% | 3,348.96+28.5% | 3,440.37+26.6% |
Balance sheet, annual
| Metric | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 | 2018FY12/31/2018 | 2017FY12/31/2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 388.95+21.3% | 320.56+16.2% | 275.85-17.2% | 333.29+13.0% | 294.86+70.6% | 172.79-40.9% | 292.46+16.0% | 252.06+70.2% | 148.08 |
| Short Term Receivables | 26.08+40.9% | 18.51+24.5% | 14.87+139.1% | 6.22+509.8% | 1.02 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 25.75+37.4% | 18.74+117.4% | 8.62+195.2% | 2.92 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 26.13+59.5% | 16.38+83.4% | 8.93-24.4% | 11.81-5.6% | 12.51+40.9% | 8.88-10.8% | 9.95+50.1% | 6.63+156.0% | 2.59 |
| Total Current Assets | 466.92+24.8% | 374.20+21.4% | 308.27-13.0% | 354.24+14.9% | 308.39+69.8% | 181.67-39.9% | 302.40+16.9% | 258.69+71.7% | 150.67 |
| Net Property, Plant & Equipment | 4.15+1.0% | 4.11+93.9% | 2.12-37.3% | 3.38-21.9% | 4.33-13.4% | 5.00-12.6% | 5.72+410.7% | 1.12+33.3% | 0.84 |
| Total Investments and Advances | 0.52+13.0% | 0.46+39.4% | 0.330.0% | 0.330.0% | 0.33-17.5% | 0.400.0% | 0.400.0% | 0.40+73.9% | 0.23 |
| Intangible Assets | 5.32-13.8% | 6.17-12.2% | 7.03-10.8% | 7.88+69.1% | 4.66 | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Tax Assets | 1.00-16.7% | 1.20 | - | - | - | - | - | - | - |
| Other Assets | 3.29-55.1% | 7.33-51.1% | 15.00-10.0% | 16.66+41.1% | 11.81 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Assets | 481.19+22.3% | 393.47+18.2% | 332.75-13.0% | 382.48+16.1% | 329.52+76.1% | 187.07-39.4% | 308.52+18.6% | 260.21+71.5% | 151.74 |
| Short Term Debt Incl. Current Port. of LT Debt | 7.95+416.2% | 1.54+100.0% | 0.77+13.2% | 0.68+11.5% | 0.61+13.0% | 0.54+14.9% | 0.47 | 0.00 | 0.00 |
| Accounts Payable | 13.95+13.1% | 12.33+152.7% | 4.88+1.7% | 4.80-16.4% | 5.74+17.1% | 4.90-52.9% | 10.41+36.3% | 7.64+214.4% | 2.43 |
| Other Current Liabilities | 84.05-17.3% | 101.65+105.1% | 49.55+44.3% | 34.33-7.4% | 37.08+195.2% | 12.56-7.2% | 13.53+127.8% | 5.94+38.5% | 4.29 |
| Total Current Liabilities | 105.94-8.3% | 115.52+109.3% | 55.20+38.7% | 39.81-8.3% | 43.43+141.4% | 17.99-26.3% | 24.42+79.8% | 13.58+102.1% | 6.72 |
| Long Term Debt | 235.19-7.8% | 255.03+139.2% | 106.63+38.4% | 77.07+3852.3% | 1.95-23.5% | 2.55-17.5% | 3.09 | 0.00 | 0.00 |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Tax Liabilities | 1.00-16.7% | 1.20 | - | - | - | - | - | - | - |
| Other Liabilities | 0.00 | 0.00-100.0% | 1.15-14.2% | 1.34 | 0.00 | 0.00 | 0.00-100.0% | 0.37+60.9% | 0.23 |
| Total Liabilities | 342.12-8.0% | 371.75+128.1% | 162.99+37.9% | 118.22+160.6% | 45.37+120.8% | 20.55-25.3% | 27.50+97.1% | 13.95+100.7% | 6.95 |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | 139.07+540.0% | 21.73-87.2% | 169.76-35.8% | 264.26-7.0% | 284.15+70.6% | 166.53-40.7% | 281.02+14.1% | 246.26+70.1% | 144.79 |
| Total Shareholders Equity | 139.07+540.0% | 21.73-87.2% | 169.76-35.8% | 264.26-7.0% | 284.15+70.6% | 166.53-40.7% | 281.02+14.1% | 246.26+70.1% | 144.79 |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 139.07+540.0% | 21.73-87.2% | 169.76-35.8% | 264.26-7.0% | 284.15+70.6% | 166.53-40.7% | 281.02+14.1% | 246.26+70.1% | 144.79 |
| Total Liabilities & Stockholders Equity | 481.19+22.3% | 393.47+18.2% | 332.75-13.0% | 382.48+16.1% | 329.52+76.1% | 187.07-39.4% | 308.52+18.6% | 260.21+71.5% | 151.74 |
| Book Value Per Share per share | 2.07+491.4% | 0.35-87.8% | 2.86-38.8% | 4.67-17.3% | 5.65+50.3% | 3.76-41.2% | 6.39-10.8% | 7.16+34.8% | 5.31 |
| Tangible Book Value Per Share per share | 1.99+696.0% | 0.25-90.9% | 2.74-39.5% | 4.53-18.5% | 5.56+47.9% | 3.76-41.2% | 6.39-10.8% | 7.16+34.8% | 5.31 |
| Full-Time Employees people | 414+46.3% | 283+25.2% | 226+27.7% | 177+26.4% | 140+55.6% | 90+28.6% | 70+29.6% | 54+107.7% | 26 |
| Price to Book Ratio ratio | 86.57 | 306.66 | 13.76 | 5.77 | 1.77 | 7.90 | 3.59 | 3.76 | -0.99 |
| Return on Assets % | -44.94 | -71.77 | -51.64 | -50.88 | -26.95 | -54.07 | -49.49 | -35.96 | -45.81 |
| Return on Equity % | -244.45 | -272.19 | -85.10 | -66.05 | -30.89 | -59.88 | -53.38 | -37.88 | -49.42 |
| Return on Invested Capital % | -52.51 | -94.16 | -66.82 | -53.06 | -24.33 | -79.25 | -49.53 | -30.08 | -25.96 |
| Quick Ratio ratio | 4.16 | 3.08 | 5.43 | 8.83 | 7.10 | 10.10 | 12.38 | 19.05 | 22.42 |
| Current Ratio ratio | 4.41 | 3.24 | 5.58 | 8.90 | 7.10 | 10.10 | 12.38 | 19.05 | 22.42 |
Cash flow, annual
| Metric | TTM | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 | 2018FY12/31/2018 |
|---|---|---|---|---|---|---|---|---|---|
| Net Income | -193.81 | -196.54 | -260.60 | -184.68 | -181.12 | -69.61 | -134.00 | -140.73 | -74.06 |
| Depreciation | 1.02 | 1.34-14.1% | 1.56-11.4% | 1.76+24.8% | 1.41+21.6% | 1.16+68.1% | 0.69-16.9% | 0.83+88.6% | 0.44 |
| Other Funds (Non Cash) | 108.43 | 80.49-40.2% | 134.59+220.8% | 41.96+61.3% | 26.01 | -79.45-561.4% | 17.22+42.5% | 12.08+10.8% | 10.90 |
| Funds from Operations | -84.36 | -114.71 | -124.45 | -140.96 | -153.70 | -147.90 | -116.08 | -127.82 | -62.72 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | 2.57 | -0.97-109.2% | 10.57+119.8% | 4.81 | -19.72-1137.9% | 1.90 | -5.89-216.2% | 5.07+656.7% | 0.67 |
| Cash from Operating Activities | -81.79 | -115.67 | -113.88 | -136.16 | -173.43 | -146.00 | -121.98 | -122.75 | -62.06 |
| Capital Expenditures | -1.45 | -40.95 | -40.50 | -5.71 | -4.28 | -5.43 | -0.21 | -3.38 | -0.72 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Sale of Fixed Assets and Businesses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Purchase or Sale of Investments | 86.76 | -96.20 | -7.67-15440.0% | 0.05-99.8% | 32.31 | -163.72-203.1% | 158.75 | -24.59 | -86.43 |
| Purchase of Investments | -197.02 | -348.67 | -268.31 | -354.92 | -251.94 | -524.97 | -86.87 | -295.82 | -248.59 |
| Sale Or Maturity of Investments | 283.78 | 252.47-3.1% | 260.64-26.6% | 354.97+24.9% | 284.25-21.3% | 361.25+47.1% | 245.61-9.4% | 271.24+67.3% | 162.17 |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 107.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | 85.31 | -137.15 | -48.17 | -5.67-120.2% | 28.03 | -62.16-139.2% | 158.53 | -27.97 | -87.15 |
| Cash Dividends Paid | -1.46 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | 24.44 | 237.88+21.8% | 195.24+240.1% | 57.40-59.4% | 141.49-15.0% | 166.48+8182.6% | 2.01-98.8% | 163.47-0.7% | 164.69 |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 24.44 | 237.88+21.8% | 195.24+240.1% | 57.40-59.4% | 141.49-15.0% | 166.48+8182.6% | 2.01-98.8% | 163.47-0.7% | 164.69 |
| Proceedsfrom Stock Options | 2.16 | 224.28+25.1% | 179.27+259.0% | 49.93-62.1% | 131.74-18.9% | 162.35+31121.2% | 0.52-99.7% | 161.91-1.7% | 164.69 |
| Issuance or Reduction of Debt, Net | -24.53 | -19.92 | -12.90 | -7.40 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Long Term Debt | -24.53 | -19.92 | -12.90 | -7.40 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Issuance of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | -24.53 | -19.92 | -12.90 | -7.40 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Financing Active Other Cash Flow | -14.22 | 0.00-100.0% | 8.90-63.5% | 24.37-66.3% | 72.34 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Activities Uses | -14.22 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Financing Activities | -15.76 | 217.96+14.0% | 191.24+157.1% | 74.37-65.2% | 213.83+28.4% | 166.48+8182.6% | 2.01-98.8% | 163.47-0.7% | 164.69 |
| Exchange Rate Effect | 0.76 | 0.09 | 0.00 | -0.14 | - | - | - | - | - |
| Net Change in Cash | -11.49 | -34.78-219.2% | 29.19 | -67.60-198.8% | 68.43 | -41.68-208.1% | 38.56+202.4% | 12.75-17.6% | 15.48 |
| Free Cash Flow | -83.24 | -116.63 | -113.88 | -136.20 | -173.71 | -146.44 | -122.19 | -126.14 | -62.78 |
| Preferred Dividends (Cash Flow) | - | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Taxes & Investment Tax Credit | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Balance sheet, quarterly
| Metric | 2026Q39/30/2026 | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 320.94-22.9% | 330.90+13.7% | 340.62+8.3% | 388.95+21.3% | 416.05+39.4% | 291.03-8.8% | 314.49+56.3% | 320.56+16.2% |
| Short Term Receivables | 39.12+18.4% | 40.41+54.7% | 34.19+91.9% | 26.08+40.9% | 33.03+71.1% | 26.12+48.4% | 17.82+21.2% | 18.51+24.5% |
| Inventories | 31.19+41.1% | 30.52+61.7% | 28.65+48.3% | 25.75+37.4% | 22.11+59.2% | 18.87+57.4% | 19.32+127.0% | 18.74+117.4% |
| Other Current Assets | 28.11+19.1% | 24.74+0.3% | 26.62+50.7% | 26.13+59.5% | 23.61+169.8% | 24.66+185.4% | 17.66+55.6% | 16.38+83.4% |
| Total Current Assets | 419.36-15.2% | 426.56+18.3% | 430.09+16.5% | 466.92+24.8% | 494.80+45.4% | 360.68+0.9% | 369.29+56.6% | 374.20+21.4% |
| Net Property, Plant & Equipment | 3.26-4.1% | 2.92-18.0% | 4.00+4.4% | 4.15+1.0% | 3.40-22.6% | 3.56-23.8% | 3.83+110.4% | 4.11+93.9% |
| Total Investments and Advances | 1.28+91.0% | 0.60+13.2% | 0.60+30.4% | 0.52+13.0% | 0.67+45.7% | 0.53+15.2% | 0.460.0% | 0.46+39.4% |
| Intangible Assets | 16.68+201.6% | 4.89-15.0% | 5.11-14.3% | 5.32-13.8% | 5.53-13.5% | 5.75-12.9% | 5.96-12.6% | 6.17-12.2% |
| Deferred Tax Assets | - | - | - | 1.00-16.7% | - | - | - | 1.20 |
| Other Assets | 2.55+3.2% | 2.29+3.2% | 2.52-64.7% | 3.29-55.1% | 2.47-79.4% | 2.22-82.6% | 7.14-48.3% | 7.33-51.1% |
| Total Assets | 443.13-12.6% | 437.27+17.3% | 442.32+14.4% | 481.19+22.3% | 506.87+39.4% | 372.73-2.4% | 386.69+49.5% | 393.47+18.2% |
| Short Term Debt Incl. Current Port. of LT Debt | 15.48+150.5% | 13.41+212.6% | 10.81+497.2% | 7.95+416.2% | 6.18 | 4.29+423.2% | 1.81+129.1% | 1.54+100.0% |
| Accounts Payable | 10.69-21.6% | 16.16+1.1% | 12.30+3.3% | 13.95+13.1% | 13.63+178.7% | 15.98+252.0% | 11.91+57.7% | 12.33+152.7% |
| Other Current Liabilities | 124.72+47.7% | 94.02-13.9% | 80.09-18.4% | 84.05-17.3% | 84.46-8.9% | 109.19+121.2% | 98.10+114.1% | 101.65+105.1% |
| Total Current Liabilities | 150.89+44.7% | 123.59-4.5% | 103.20-7.7% | 105.94-8.3% | 104.27+6.8% | 129.46+136.6% | 111.82+106.5% | 115.52+109.3% |
| Long Term Debt | 90.70-64.3% | 96.38-62.2% | 216.21-15.5% | 235.19-7.8% | 253.79-0.4% | 255.19+1.3% | 255.91+137.7% | 255.03+139.2% |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Tax Liabilities | - | - | - | 1.00-16.7% | - | - | - | 1.20 |
| Other Liabilities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 0.00-100.0% | 0.00-100.0% |
| Total Liabilities | 241.59-32.5% | 219.97-42.8% | 319.41-13.1% | 342.12-8.0% | 358.06+1.6% | 384.64+12.3% | 367.74+86.6% | 371.75+128.1% |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 113.58 | 114.32 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | 87.97-40.9% | 102.98 | 122.91+548.6% | 139.07+540.0% | 148.82+1227.6% | -11.91-130.3% | 18.95-69.2% | 21.73-87.2% |
| Total Shareholders Equity | 201.54+35.4% | 217.30 | 122.91+548.6% | 139.07+540.0% | 148.82+1227.6% | -11.91-130.3% | 18.95-69.2% | 21.73-87.2% |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 201.54+35.4% | 217.30 | 122.91+548.6% | 139.07+540.0% | 148.82+1227.6% | -11.91-130.3% | 18.95-69.2% | 21.73-87.2% |
| Total Liabilities & Stockholders Equity | 443.13-12.6% | 437.27+17.3% | 442.32+14.4% | 481.19+22.3% | 506.87+39.4% | 372.73-2.4% | 386.69+49.5% | 393.47+18.2% |
| Book Value Per Share per share | 1.27-43.0% | 1.50 | 1.80+500.0% | 2.07+491.4% | 2.23+1138.9% | -0.19-129.7% | 0.30-70.3% | 0.35-87.8% |
| Tangible Book Value Per Share per share | 1.03-52.1% | 1.43 | 1.72+760.0% | 1.99+696.0% | 2.15+2587.5% | -0.28-151.9% | 0.20-77.8% | 0.25-90.9% |
| Full-Time Employees people | - | - | - | 414+46.3% | - | - | - | 283+25.2% |
| Price to Book Ratio ratio | 86.57 | 61.83 | 42.03 | 47.96 | -542.02 | 211.76 | 152.09 | 306.66 |
| Return on Assets % | -40.80 | -50.70 | -48.90 | -44.94 | -44.19 | -48.52 | -52.28 | -71.76 |
| Return on Equity % | -110.64 | -199.95 | -285.76 | -244.45 | -240.36 | -1,334.54 | -418.97 | -272.15 |
| Return on Invested Capital % | -14.16 | -15.72 | -16.41 | -12.69 | -13.14 | -19.17 | -18.01 | -15.64 |
| Quick Ratio ratio | 2.57 | 3.20 | 3.89 | 4.16 | 4.53 | 2.64 | 3.13 | 3.08 |
| Current Ratio ratio | 2.78 | 3.45 | 4.17 | 4.41 | 4.75 | 2.79 | 3.30 | 3.24 |
Cash flow, quarterly
| Metric | 2026Q39/30/2026 | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -41.37 | -49.30 | -55.64 | -47.51 | -52.90 | -46.63 | -49.50 | -43.29 |
| Depreciation | 0.25-16.7% | 0.25-34.2% | 0.25-34.2% | 0.27-28.9% | 0.30-23.1% | 0.38-2.6% | 0.38-7.3% | 0.38+216.7% |
| Other Funds (Non Cash) | 28.44+24.4% | 29.24+58.8% | 28.21+69.2% | 22.54+62.6% | 22.87+70.9% | 18.41+272.7% | 16.67-83.7% | 13.86+330.4% |
| Funds from Operations | -12.68 | -19.80 | -27.17 | -24.70 | -29.73 | -27.84 | -32.44 | -29.05 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | 9.62+209.3% | 10.65+135.1% | -17.01 | -0.69-106.8% | 3.11-33.8% | 4.53 | -7.91 | 10.21+14.6% |
| Cash from Operating Activities | -3.06 | -9.15 | -44.19 | -25.39 | -26.62 | -23.31 | -40.35 | -18.84 |
| Capital Expenditures | -0.50 | 0.00 | 0.00 | -0.95 | -40.00 | 0.00 | 0.00 | 0.00 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase or Sale of Investments | -15.61 | 14.01-74.1% | 57.05+129.9% | 31.30+47.9% | -206.35 | 54.03 | 24.81-64.6% | 21.16-6.5% |
| Purchase of Investments | -90.99 | -43.49 | -42.20 | -20.35 | -267.85 | -26.95 | -33.52 | -66.38 |
| Sale Or Maturity of Investments | 75.38+22.6% | 57.50-29.0% | 99.25+70.2% | 51.65-41.0% | 61.50+35.8% | 80.99+40.2% | 58.33-16.7% | 87.53+38.3% |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | -16.11 | 14.01-74.1% | 57.05+129.9% | 30.35+43.4% | -246.35 | 54.03 | 24.81-17.4% | 21.16-6.5% |
| Cash Dividends Paid | -1.46 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | 7.65-96.7% | 7.00+103.5% | 7.35+138.6% | 2.45-94.2% | 228.91+3826.4% | 3.44-97.5% | 3.08-56.2% | 42.14+742.8% |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 7.65-96.7% | 7.00+103.5% | 7.35+138.6% | 2.45-94.2% | 228.91+3826.4% | 3.44-97.5% | 3.08-56.2% | 42.14+742.8% |
| Proceedsfrom Stock Options | 0.91-99.6% | 0.00 | 1.25+47.1% | 0.00-100.0% | 223.42+37136.7% | 0.00-100.0% | 0.85+26.9% | 39.15 |
| Issuance or Reduction of Debt, Net | -7.93 | -6.91 | -4.29 | -5.40 | -5.57 | -4.33 | -4.62 | -3.81 |
| Change in Long Term Debt | -7.93 | -6.91 | -4.29 | -5.40 | -5.57 | -4.33 | -4.62 | -3.81 |
| Issuance of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | -7.93 | -6.91 | -4.29 | -5.40 | -5.57 | -4.33 | -4.62 | -3.81 |
| Net Financing Active Other Cash Flow | -4.50 | -1.26 | -8.46-124.9% | 0.00 | -34.03 | 0.00-100.0% | 34.03 | 0.00 |
| Other Financing Activities Uses | -4.50 | -1.26 | -8.46 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Financing Activities | -6.25-103.3% | -1.17 | -5.40-116.6% | -2.95-107.7% | 189.30+7502.4% | -0.89-100.6% | 32.50+666.5% | 38.33+1483.9% |
| Exchange Rate Effect | 0.46+53.3% | -0.22 | 0.45 | 0.06-93.9% | 0.30 | -0.28 | -0.00 | 0.98 |
| Net Change in Cash | -24.95 | 3.48-88.2% | 7.92-53.3% | 2.07-95.0% | -83.36 | 29.55-72.7% | 16.96 | 41.62 |
| Free Cash Flow | -3.56 | -9.15 | -44.19 | -26.34 | -26.62 | -23.31 | -40.35 | -18.84 |
Revenue breakdown
USD millions, so a column adds up to the income statement. Share is of the latest year in that split. The change is versus the older year shown, not TTM.
| Name | 2024 | 2025 | vs 2024 | 2025 share |
|---|---|---|---|---|
| Pharmaceutical Preparations | 130.13 | 189.76 | +45.8% | 100.0% |
| Total | 130.13 | 189.76 | +45.8% | 100.0% |
| Name | 2024 | 2025 | vs 2024 | 2025 share |
|---|---|---|---|---|
| License | - | -5.01 | - | -2.6% |
| Non-US | 34.02 | - | - | - |
| Product | - | 194.77 | - | 102.6% |
| United States | 96.11 | - | - | - |
| Total | 130.13 | 189.76 | +45.8% | 100.0% |
Short interest
shares short against float, oldest to newest| Settlement | Of float | Shares short | Float | Avg volume |
|---|---|---|---|---|
| 2026-10-30 | 17.53% | 11.7M | 66.6M | 655.80K |
| 2026-10-15 | 16.64% | 11.0M | 66.1M | 671.75K |
| 2026-09-30 | 16.28% | 10.8M | 66.1M | 650.01K |
| 2026-09-15 | 15.56% | 10.3M | 66.1M | 730.75K |
| 2026-08-31 | 15.58% | 10.3M | 66.1M | 758.49K |
| 2026-08-14 | 15.36% | 10.2M | 66.1M | 773.41K |
| 2026-07-31 | 14.16% | 9.4M | 66.7M | 807.69K |
| 2026-07-15 | 14.42% | 9.6M | 66.4M | 805.57K |
| 2026-06-30 | 14.56% | 9.7M | 66.4M | 810.27K |
| 2026-06-15 | 12.05% | 8.0M | 66.4M | 809.03K |
| 2026-05-29 | 11.91% | 7.9M | 66.4M | 837.99K |
| 2026-05-15 | 12.48% | 8.3M | 66.4M | 870.61K |
| 2026-04-30 | 12.59% | 8.1M | 64.0M | 828.45K |
| 2026-04-15 | 12.28% | 7.8M | 63.8M | 828.47K |
| 2026-03-31 | 11.98% | 7.6M | 63.7M | 832.58K |
| 2026-03-13 | 10.27% | 6.5M | 63.7M | 739.68K |
| 2026-02-27 | 9.93% | 6.3M | 63.7M | 772.60K |
| 2026-02-13 | 9.68% | 6.0M | 62.2M | 761.57K |
| 2026-01-30 | 10.02% | 6.2M | 62.2M | 766.74K |
| 2026-01-15 | 10.08% | 6.3M | 62.3M | 765.53K |
Option chain
expiry 2026-11-20| Type | Strike | Bid | Ask | Last | IV | Open int | Volume | Delta | Theta | Vega |
|---|---|---|---|---|---|---|---|---|---|---|
| call | 50.00 | 57.50 | 62.10 | 57.80 | 4.202 | 7.00 | 0.00 | 0.980 | -0.150 | 0.008 |
| call | 55.00 | 52.50 | 57.10 | 0.00 | 3.768 | 0.00 | 0.00 | 0.978 | -0.148 | 0.009 |
| call | 60.00 | 47.50 | 52.20 | 0.00 | 3.372 | 0.00 | 0.00 | 0.975 | -0.146 | 0.009 |
| call | 65.00 | 42.50 | 47.20 | 0.00 | 3.008 | 0.00 | 0.00 | 0.972 | -0.143 | 0.010 |
| call | 70.00 | 37.50 | 42.10 | 0.00 | 2.668 | 0.00 | 0.00 | 0.968 | -0.140 | 0.012 |
| call | 75.00 | 32.50 | 37.00 | 0.00 | 2.385 | 0.00 | 0.00 | 0.963 | -0.137 | 0.013 |
| call | 80.00 | 27.50 | 32.00 | 0.00 | 2.080 | 0.00 | 0.00 | 0.954 | -0.144 | 0.015 |
| call | 85.00 | 22.50 | 27.00 | 7.30 | 1.788 | 4.00 | 0.00 | 0.929 | -0.187 | 0.022 |
| call | 90.00 | 17.70 | 21.80 | 21.20 | 1.397 | 373 | 1.00 | 0.915 | -0.177 | 0.025 |
| call | 95.00 | 13.30 | 16.90 | 15.00 | 1.181 | 1,045 | 0.00 | 0.824 | -0.321 | 0.042 |
| call | 100 | 8.80 | 13.00 | 14.00 | 1.033 | 20.00 | 0.00 | 0.781 | -0.286 | 0.048 |
| call | 105 | 4.80 | 9.00 | 8.90 | 0.890 | 205 | 0.00 | 0.686 | -0.275 | 0.057 |
| call | 110 | 2.40 | 6.10 | 4.20 | 0.954 | 158 | 95.00 | 0.527 | -0.401 | 0.064 |
| call | 115 | 0.25 | 5.00 | 2.45 | 1.072 | 24.00 | 6.00 | 0.419 | -0.438 | 0.063 |
| call | 120 | 0.00 | 1.45 | 1.45 | 0.734 | 421 | 76.00 | 0.230 | -0.236 | 0.049 |
| call | 125 | 0.60 | 5.00 | 0.75 | 0.922 | 58.00 | 4.00 | 0.189 | -0.259 | 0.044 |
| call | 130 | 0.00 | 5.00 | 0.45 | 1.091 | 40.00 | 4.00 | 0.167 | -0.282 | 0.040 |
| call | 135 | 0.00 | 5.00 | 0.00 | 1.246 | 0.00 | 0.00 | 0.151 | -0.301 | 0.038 |
| call | 140 | 0.00 | 5.00 | 0.00 | 1.390 | 0.00 | 0.00 | 0.139 | -0.318 | 0.036 |
| call | 145 | 0.00 | 5.00 | 0.00 | 1.524 | 0.00 | 0.00 | 0.130 | -0.332 | 0.034 |
| call | 150 | 0.00 | 5.00 | 0.00 | 1.650 | 0.00 | 0.00 | 0.122 | -0.345 | 0.033 |
| call | 155 | 0.00 | 5.00 | 2.70 | 1.769 | 1.00 | 0.00 | 0.116 | -0.356 | 0.031 |
| call | 160 | 0.00 | 5.00 | 2.10 | 1.882 | 1.00 | 0.00 | 0.111 | -0.366 | 0.030 |
| call | 165 | 0.00 | 5.00 | 0.00 | 1.989 | 0.00 | 0.00 | 0.106 | -0.376 | 0.030 |
| call | 170 | 0.00 | 5.00 | 0.00 | 2.092 | 0.00 | 0.00 | 0.102 | -0.384 | 0.029 |
| call | 175 | 0.00 | 5.00 | 0.00 | 2.190 | 0.00 | 0.00 | 0.099 | -0.392 | 0.028 |
| put | 50.00 | 0.00 | 4.90 | 0.00 | 2.921 | 0.00 | 0.00 | -0.020 | -0.144 | 0.008 |
| put | 55.00 | 0.00 | 4.90 | 0.00 | 2.603 | 0.00 | 0.00 | -0.022 | -0.142 | 0.009 |
| put | 60.00 | 0.00 | 5.00 | 0.00 | 2.313 | 0.00 | 0.00 | -0.025 | -0.139 | 0.009 |
| put | 65.00 | 0.00 | 5.00 | 0.00 | 2.044 | 0.00 | 0.00 | -0.028 | -0.136 | 0.010 |
| put | 70.00 | 0.00 | 5.00 | 0.00 | 1.794 | 0.00 | 0.00 | -0.032 | -0.132 | 0.012 |
| put | 75.00 | 0.00 | 0.40 | 0.10 | 1.531 | 70.00 | 0.00 | -0.035 | -0.116 | 0.013 |
| put | 80.00 | 0.00 | 0.45 | 0.15 | 1.355 | 7.00 | 0.00 | -0.043 | -0.122 | 0.016 |
| put | 85.00 | 0.00 | 5.00 | 0.34 | 1.279 | 0.00 | 0.00 | -0.071 | -0.178 | 0.022 |
| put | 90.00 | 0.00 | 0.70 | 1.45 | 1.067 | 52.00 | 0.00 | -0.088 | -0.174 | 0.026 |
| put | 95.00 | 0.00 | 5.00 | 0.24 | 1.180 | 109 | 0.00 | -0.176 | -0.311 | 0.042 |
| put | 100 | 0.00 | 1.95 | 0.95 | 0.909 | 60.00 | 1.00 | -0.219 | -0.274 | 0.047 |
| put | 105 | 0.00 | 2.20 | 1.20 | 0.692 | 238 | 0.00 | -0.305 | -0.265 | 0.057 |
| put | 110 | 2.00 | 6.60 | 3.50 | 0.978 | 1.00 | 0.00 | -0.473 | -0.389 | 0.064 |
| put | 115 | 5.10 | 10.00 | 0.00 | 1.050 | 0.00 | 0.00 | -0.586 | -0.409 | 0.063 |
| put | 120 | 9.00 | 13.90 | 14.70 | 1.177 | 1.00 | 0.00 | -0.769 | -0.225 | 0.049 |
| put | 125 | 13.50 | 18.30 | 0.00 | 1.271 | 0.00 | 0.00 | -0.811 | -0.245 | 0.044 |
| put | 130 | 18.00 | 22.90 | 0.00 | 1.384 | 0.00 | 0.00 | -0.833 | -0.268 | 0.040 |
| put | 135 | 23.00 | 27.80 | 0.00 | 1.514 | 0.00 | 0.00 | -0.849 | -0.286 | 0.038 |
| put | 140 | 27.70 | 32.50 | 0.00 | 1.649 | 0.00 | 0.00 | -0.861 | -0.302 | 0.036 |
| put | 145 | 32.60 | 37.50 | 0.00 | 1.795 | 0.00 | 0.00 | -0.870 | -0.316 | 0.034 |
| put | 150 | 37.80 | 42.50 | 0.00 | 1.932 | 0.00 | 0.00 | -0.878 | -0.328 | 0.033 |
| put | 155 | 42.80 | 47.50 | 0.00 | 2.062 | 0.00 | 0.00 | -0.884 | -0.339 | 0.031 |
| put | 160 | 47.80 | 52.50 | 0.00 | 2.185 | 0.00 | 0.00 | -0.889 | -0.349 | 0.030 |
| put | 165 | 52.80 | 57.50 | 0.00 | 2.302 | 0.00 | 0.00 | -0.894 | -0.357 | 0.030 |
| put | 170 | 57.80 | 62.50 | 0.00 | 2.414 | 0.00 | 0.00 | -0.898 | -0.366 | 0.029 |
| put | 175 | 62.60 | 67.50 | 0.00 | 2.492 | 0.00 | 0.00 | -0.901 | -0.373 | 0.028 |
Latest SEC filings
30| Filed | Form | Description | Period | Link |
|---|---|---|---|---|
| 2026-11-03 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-09-30 | SEC |
| 2026-11-03 | 8-K | Current report | 2026-11-03 | SEC |
| 2026-10-13 | SCHEDULE 13G | SEC | ||
| 2026-09-14 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-09-14 | 4 | Statement of changes in beneficial ownership of securities | 2026-09-14 | SEC |
| 2026-09-01 | 4 | Statement of changes in beneficial ownership of securities | 2026-08-31 | SEC |
| 2026-08-31 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-08-18 | 4 | Statement of changes in beneficial ownership of securities | 2026-08-17 | SEC |
| 2026-08-18 | 3 | Initial statement of beneficial ownership of securities | 2026-08-17 | SEC |
| 2026-08-17 | 4 | Statement of changes in beneficial ownership of securities | 2026-08-13 | SEC |
| 2026-08-17 | 4 | Statement of changes in beneficial ownership of securities | 2026-08-13 | SEC |
| 2026-08-14 | 4 | Statement of changes in beneficial ownership of securities | 2026-08-13 | SEC |
| 2026-08-14 | 4 | Statement of changes in beneficial ownership of securities | 2026-08-12 | SEC |
| 2026-08-13 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-08-13 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-08-13 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-08-12 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-08-11 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-08-10 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-08-04 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-06-30 | SEC |
| 2026-08-04 | 8-K | Current report | 2026-08-04 | SEC |
| 2026-07-02 | 4 | Statement of changes in beneficial ownership of securities | 2026-07-01 | SEC |
| 2026-06-25 | 8-K | Current report | 2026-06-24 | SEC |
| 2026-06-25 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-23 | SEC |
| 2026-06-25 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-23 | SEC |
| 2026-06-25 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-23 | SEC |
| 2026-06-25 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-23 | SEC |
| 2026-06-25 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-23 | SEC |
| 2026-06-24 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-22 | SEC |
| 2026-06-22 | 144 | Filing for proposed sale of securities under Rule 144. | SEC |
Insider activity by month
| Month | Bought | Buys | Sold | Sells |
|---|---|---|---|---|
| 2026-11 | 0 | 0 | 0 | 0 |
| 2026-10 | 0 | 0 | 0 | 0 |
| 2026-09 | 0 | 0 | 5.13M | 1 |
| 2026-08 | 0 | 0 | 23.66M | 5 |
| 2026-07 | 0 | 0 | 0 | 0 |
| 2026-06 | 0 | 0 | 3.71M | 1 |
| 2026-05 | 0 | 0 | 428.13K | 1 |
| 2026-04 | 0 | 0 | 0 | 0 |
| 2026-03 | 0 | 0 | 502.79K | 1 |
| 2026-02 | 0 | 0 | 2.22M | 7 |
| 2026-01 | 0 | 0 | 0 | 0 |
| 2025-12 | 0 | 0 | 371.85K | 1 |
| 2025-11 | 0 | 0 | 2.62M | 3 |
Institutional holders
| Manager | % owned |
|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 9.72% |
| BlackRock, Inc. | 8.98% |
| BAKER BROS. ADVISORS LP | 8.17% |
| JPMORGAN CHASE & CO | 5.17% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 4.57% |
| PRIMECAP MANAGEMENT CO/CA/ | 4.45% |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.38% |
| STATE STREET CORP | 3.83% |
| PERCEPTIVE ADVISORS LLC | 3.77% |
| PRICE T ROWE ASSOCIATES INC /MD/ | 3.74% |
Funds
| Fund | % owned |
|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND | 3.17% |
| PRIMECAP Odyssey Aggressive Growth Fund | 2.87% |
| SMALLCAP World Fund Inc | 2.49% |
| VANGUARD SMALL-CAP INDEX FUND | 2.29% |
| iShares Russell 2000 ETF | 2.07% |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 1.69% |
| Federated Hermes Kaufmann Fund | 1.50% |
| PRIMECAP Odyssey Growth Fund | 1.47% |
| VANGUARD SMALL-CAP GROWTH INDEX FUND | 1.32% |
| T. Rowe Price New Horizons Fund, Inc. | 1.14% |
OakChart. RYTM. Cached 15 minutes. Terms